3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 2
4
Phase NA
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Rhabdomyosarcoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Everolimus
10
lutetium Lu 177 dotatate
5
Magnetic Resonance Spectroscopy
5
pasireotide
4
Specimen Handling
3
Positron Emission Tomography Computed Tomography
3
Fluorodeoxyglucose F18
3
(177)Lu-DOTA-EB-TATE
3
olaparib
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
FAPI-46
2
veliparib
1
vandetanib
1
trifluridine tipiracil drug combination
1
toripalimab
1
tislelizumab
1
talazoparib
1
surufatinib
1
romidepsin
1
peposertib
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
fosbretabulin
1
fludarabine phosphate
1
exemestane
1
decitabine and cedazuridine drug combination
1
dactolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neuroendocrine Tumors
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled